BLTE

Belite Bio (BLTE)

About Belite Bio (BLTE)

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Details

Daily high

$153.48

Daily low

$146.61

Price at open

52 Week High

$200.00

52 Week Low

$49.00

Market cap

5.9B

Dividend yield

0.00%

Volume

552

Avg. volume

195,038

P/E ratio

-65.64

Belite Bio News